Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study

D. De Berardis*, M. Fornaro, A. Anastasia, F. Vellante, L. Olivieri, G. Rapini, N. Serroni, L. Orsolini, A. Valchera, A. Carano, C. Tomasetti, A. Ventriglio, M. Bustini, M. Pompili, G. Serafini, G. Perna, F. Iasevoli, G. Martinotti, M. Di Giannantonio

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review


Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD.

Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores

Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D score was observed (p

Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant depression. However, the limitations of this study (such as small sample size, absence of randomization and control group, retrospective design, etc.) must be considered.

Original languageEnglish
Pages (from-to)317-321
Number of pages5
JournalRevista Brasileira de Psiquiatria
Issue number3
Publication statusPublished - 1 May 2020


  • antidepressants
  • augmentation
  • chart study
  • pharmacokinetics
  • real world
  • retrospective
  • scale
  • ssri-resistant major depressive disorder
  • suicide
  • vortioxetine
  • SSRI-resistant major depressive disorder
  • Vortioxetine

Cite this